DUBLIN, Ireland — Perrigo Co. plc has completed its acquisition of a portfolio of generic dosage forms and strengths of acne topical treatment Retin-A from Matawan Pharmaceuticals LLC.

Financial terms of deal, announced in mid-December, weren’t disclosed. Perrigo was the authorized generic distributor of these Retin-A (tretinoin) products from 2005 to 2013 before the agreement was terminated.

“We are excited to complete this transaction, bringing a high barrier-to-entry, margin-enhancing product and greater reach to the extended topicals portfolio,” stated Perrigo chairman and chief executive officer Joseph Papa. “This acquisition further strengthens Perrigo’s strategic position as we continue our mission of providing quality affordable health care products to consumers around the world.”

Generic and brand sales of Retin-A totaled about $290 million for the 12 months ended in November 2015, Perrigo reported.

Perrigo added that the transaction is slated to add more than 20 cents in adjusted earnings per share within the first 12 months after closing, excluding estimates for intangible amortization, transaction costs and integration related expenses.